Exact Sciences’ sales slowdown spooks investors; Acelyrin CEO Shao-Lee Lin is stepping down; The monitoring of farmworkers who have been exposed to cows sick with avian influenza is severely limited.
Five things for pharma marketers to know for Thursday morning
FDA adcomm to review Lilly’s Alzheimer’s drug candidate donanemab; TikTok sues the federal government to avoid ban; Zenas BioPharma closes a $200 million Series C funding round.
Five things for pharma marketers to know for Tuesday morning
What comes after White House punts on the menthol cigarette ban?; Johnson & Johnson re-adds Israel to its directory of global markets; Secretary of State Antony Blinken meets with biotech experts.
Five things for pharma marketers to know for Thursday morning
Eli Lilly’s Mounjaro has limited availability through February; Samsung Biologics says its net profit fell 21.4% in Q4 2023 due largely to a one-off factor; The FDA denies approval for a newer formulation of tesamorelin that Theratechnologies proposed.
Five things for pharma marketers to know for Monday morning
Will Bernie Sanders subpoena Big Pharma execs?; Drugmakers raise the list prices for Ozempic and Mounjaro; Scientists identify a persistent change in a handful of blood proteins in people with long COVID.
Five things for pharma marketers to know on Tuesday morning
Novartis in talks to buy Cytokinetics; Boston Scientific acquires medtech company Axonics in $3.7 billion deal; Lilly’s Zepbound obesity drug reaches 25,000 new prescriptions mark.
Five things for pharma marketers to know on Tuesday
Medical complications rise at hospitals bought by PE firms; BMS snaps up radiation cancer therapy firm; Government ban on certain Apple Watches kicks in.